Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.

• Conditions: Allogene MSCs Transplantation; Chronic Liver Diseases Patients; Peripheral Vein

• Registration Number: NCT01256125
• Lead Sponsor: Sun Yat-sen University

Brief Summary

Allogene MSCs transplantation will be performed in patients with chronic liver diseases through peripheral vein and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.

Detailed Description

Not available

Study Timeline

• Status Verified: 2010-10
• Study Start: 2010-10
• Study First Submitted: 2010-12-07
• Study First Submitted QC: 2010-12-07
• Last Update Submitted: 2010-12-07
• Study First Posted: 2010-12-08
• Last Update Posted: 2010-12-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease.
2. age: 15-65 years old.

Exclusion Criteria

1. pregnant women and women in lactation.
2. other systems and organs disfunction
3. space-occupying lesion were found in liver.
4. concurrent infection with HIV and other immunodeficiency diseases.
5. DIC and active bleeding were confirmed.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Short-term therapeutic effects at 1-8 weeks after Allogene MSCs transplantation through peripheral vein.	1-8 weeks after transplantation

Secondary Outcome Measures

Name	Time	Method
Long-term follow-up of Allogene MSCs transplantation through peripheral vein.	3-60 months

Trial Locations

Locations (1)

Department of Infectious Diseases, 3rd Affiliated Hospital of Sun Yat-sen University; 🇨🇳 GuangZhou, Guangdong, China